22348-44-3

Basic information

• Product Name: TRANS-4-(METHYLAMINO)CYCLOHEXANOL
• Synonyms: TRANS-4-(METHYLAMINO)CYCLOHEXANOL;(1r,4r)-4-(MethylaMino)cyclohexanol;trans-4-(Methylamino)cyclohexan-1-ol;trans-4-(Methylamino)
• CAS NO: 22348-44-3
• Molecular Formula: C₇H₁₅NO
• Molecular Weight: 129.2
• Mol File: 22348-44-3.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 211.7°C at 760 mmHg
• Flash Point: 86.8°C
• Appearance: /
• Density: 0.97g/cm³
• Vapor Pressure: 0.0404mmHg at 25°C
• Refractive Index: 1.479
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 15.17±0.40(Predicted)
• CAS DataBase Reference: TRANS-4-(METHYLAMINO)CYCLOHEXANOL(CAS DataBase Reference)
• NIST Chemistry Reference: TRANS-4-(METHYLAMINO)CYCLOHEXANOL(22348-44-3)
• EPA Substance Registry System: TRANS-4-(METHYLAMINO)CYCLOHEXANOL(22348-44-3)

Safety Data

• Hazardous Substances Data: 22348-44-3(Hazardous Substances Data)

Usage

General Description

TRANS-4-(METHYLAMINO)CYCLOHEXANOL is a chemical compound with the molecular formula C7H13NO. It is a cyclohexanol derivative with a methylamino group attached to the fourth carbon in the cyclohexane ring. TRANS-4-(METHYLAMINO)CYCLOHEXANOL is often used in the synthesis of pharmaceuticals and other organic compounds. It has been studied for its potential use in the treatment of various medical conditions, including as an analgesic and anti-inflammatory agent. TRANS-4-(METHYLAMINO)CYCLOHEXANOL is also used in chemical research and as a building block in the production of other chemical compounds. It is important to handle this chemical with care and follow proper safety protocols when working with it in a laboratory setting.

InChI:InChI=1/C7H15NO/c1-8-6-2-4-7(9)5-3-6/h6-9H,2-5H2,1H3/t6-,7-

Upstream product

• 111300-06-2 trans-tert-butyl 4-hydroxycyclohexylcarbamate 
• 541-41-3 chloroformic acid ethyl ester 
• 50910-54-8 trans-4-aminocyclohexanol hydrochloride 
• 579-58-8 N-methyl-(4-acetamido)phenol 
• 22906-85-0 4-methylamino-phenol; hydrochloride 
• 27489-63-0 trans-4-<(benzyloxycarbonyl)amino>cyclohexanol 

Downstream Products

• 400899-99-2 tert-butyl ((1r,4r)-4-hydroxycyclohexyl)(methyl)carbamate 
• 1356821-04-9 3',5'-O-bis(tert-butyldimethylsilyl)-2-N-[N-(trans-4-hydroxycyclohexyl)-N-methylcarbamoyl]deoxyguanosine 
• 1356821-05-0 3',5'-O-bis(tert-butyldimethylsilyl)-2-N-[N-(trans-4-levulinyloxycyclohexyl)-N-methylcarbamoyl]deoxyguanosine 
• 1356821-07-2 C₂₃H₃₂N₆O₈ 
• 1356821-06-1 5'-O-(4,4'-dimethoxytrityl)-2-N-[N-(trans-4-levulinyloxycyclohexyl)-N-methylcarbamoyl]deoxyguanosine 
• 1356821-08-3 5'-O-(4,4'-dimethoxytrityl)-2-N-[N-(trans-4-levulinyloxycyclohexyl)-N-methylcarbamoyl]deoxyguanosine 3'-(2-cyanoethyl-N,N-diisopropylphosphoramidite) 
• 1086378-73-5 N-(trans-4-hydroxycyclohexyl)-N-methylbenzo[c][1,2,5]oxadiazole-5-carboxamide 
• 1086378-82-6 N-(trans-4-methoxycyclohexyl)-N-methyl-2,1,3-benzoxadiazole-5-carboxamide 
• 1086378-85-9 N-(trans-4-methoxycyclohexyl)-N-methyl-2,1,3-benzoxadiazole-5-carbothioamide 
• 1086378-88-2 N-(cis-4-hydroxycyclohexyl)-N-methyl-2,1,3-benzoxadiazole-5-carboxamide 
• 1086378-93-9 N-methyl-N-[trans-4-(2H-tetrazol-2-yl)cyclohexyl]-2,1,3-benzoxadiazole-5-carboxamide 
• 1346763-38-9 trans-4-[{2-[({[4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2-chloro-5-methoxyphenyl]amino}carbonyl)oxy]ethyl}(methyl)amino]cyclohexylhydroxyl(di-2-thienyl)acetate 
• 1346762-55-7 trans-4-[(9-{[(2R)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}nonyl)(methyl)amino]cyclohexylhydroxy(di-2-thienyl)acetate 
• 1435516-81-6 trans-4-[[3-(6-formyl-2-oxo-1,3-benzothiazol-3(2H)-yl)propyl](methyl)amino]cyclohexyl hydroxy(di-2-thienyl)acetate 

Relevant articles and documents

BTK INHIBITOR

Provided are a series of BTK inhibitors, and specifically disclosed are a compound, pharmaceutically acceptable salt thereof, tautomer thereof or prodrug thereof represented by formula (I), (II), (III) or (IV).

NEW CYCLOHEXYLAMINE DERIVATIVES HAVING β2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES

The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

DI-SUBSTITUTED AMIDES FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES

This invention relates to compounds, pharmaceutical compositions and methods for use in the prevention and treatment of cerebral insufficiency, including enhancement of receptor functioning in synapses in brain networks responsible for basic and higher order behaviors. These brain networks, which are involved in regulation of breathing, and cognitive abilities related to memory impairment, such as is observed in a variety of dementias, in imbalances in neuronal activity between different brain regions, as is suggested in disorders such as Parkinson's disease, schizophrenia, respiratory depression, sleep apneas, attention deficit hyperactivity disorder and affective or mood disorders, and in disorders wherein a deficiency in neurotrophic factors is implicated, as well as in disorders of respiration such as overdose of an alcohol, an opiate, an opioid, a barbiturate, an anesthetic, or a nerve toxin, or where the respiratory depression results form a medical condition such as central sleep apnea, stroke- induced central sleep apnea, obstructive sleep apnea, congenital hypoventilation syndrome, obesity hypoventilation syndrome, sudden infant death syndrome, Rett syndrome, spinal cord injury, traumatic brain injury, Cheney-Stokes respiration, Ondines curse, Prader-Willi's syndrome and drowning. In a particular aspect, the invention relates to compounds useful for treatment of such conditions, and methods of using these compounds for such treatment.